# Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

> **NCT02930044** · NA · COMPLETED · sponsor: **University of Maryland, Baltimore** · enrollment: 18 (actual)

## Conditions studied

- Diabetic Ketoacidosis

## Interventions

- **OTHER:** Early administration of subcutaneous insulin glargine dose
- **OTHER:** IV insulin infusion
- **DRUG:** IV fluid repletion

## Key facts

- **NCT ID:** NCT02930044
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02930044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02930044, "Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02930044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*